Spence et al., 2008 - Google Patents
Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to …Spence et al., 2008
View PDF- Document ID
- 6248631443324882018
- Author
- Spence A
- Muzi M
- Swanson K
- O'Sullivan F
- Rockhill J
- Rajendran J
- Adamsen T
- Link J
- Swanson P
- Yagle K
- Rostomily R
- Silbergeld D
- Krohn K
- Publication year
- Publication venue
- Clinical Cancer Research
External Links
Snippet
Purpose: Hypoxia is associated with resistance to radiotherapy and chemotherapy and activates transcription factors that support cell survival and migration. We measured the volume of hypoxic tumor and the maximum level of hypoxia in glioblastoma multiforme …
- 206010021143 Hypoxia 0 title abstract description 65
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Spence et al. | Regional hypoxia in glioblastoma multiforme quantified with [18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival | |
| Kawai et al. | Correlation between 18 F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas | |
| Lawrentschuk et al. | Assessing regional hypoxia in human renal tumours using 18F‐fluoromisonidazole positron emission tomography | |
| Younes et al. | Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study | |
| Wang et al. | 18F-fluoroestradiol PET/CT measurement of estrogen receptor suppression during a phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials | |
| Wick et al. | A phase II, randomized, study of weekly APG101+ reirradiation versus reirradiation in progressive glioblastoma | |
| Xu et al. | Metabolic tumour burden assessed by 18 F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection | |
| Pacini et al. | Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study | |
| Stummer et al. | The importance of surgical resection in malignant glioma | |
| Janssen et al. | Hypoxia in head and neck cancer: how much, how important? | |
| Benz et al. | FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas | |
| Peterson et al. | A phase 2 study of 16α-[18 F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC) | |
| Le et al. | Clinical biomarkers for hypoxia targeting | |
| Apisarnthanarax et al. | Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models | |
| Verburg et al. | The absorbed dose to the blood is a better predictor of ablation success than the administered 131 I activity in thyroid cancer patients | |
| Ozretic et al. | Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients | |
| Benz et al. | 3′‐deoxy‐3′‐[18F] fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: A pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki‐67 activity and histopathologic response | |
| Vercellino et al. | Hypoxia imaging of uterine cervix carcinoma with 18F-FETNIM PET/CT | |
| Yasuda et al. | Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer | |
| Yeo et al. | Interstitial fluid pressure as a prognostic factor in cervical cancer following radiation therapy | |
| Hu et al. | Correlation of hypoxia as measured by fluorine-18 fluoroerythronitroimidazole (18 F-FETNIM) PET/CT and overall survival in glioma patients | |
| Sato et al. | Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma | |
| Strating et al. | Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging | |
| Kilgour et al. | Phase II open-label, single-arm trial to investigate the efficacy and safety of topical remetinostat gel in patients with basal cell carcinoma | |
| Tateishi et al. | 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET in human gliomas: comparative study with [18F] fluorodeoxyglucose and L-methyl-[11C] methionine PET |